ExtraLife
The Mito Stabilizer
Szeto-Schiller Peptide 31 (Elamipretide / Bendavia / MTP-131)
SS-31 (Elamipretide) is a cell-permeable tetrapeptide that selectively targets the inner mitochondrial membrane by binding to cardiolipin. It represents a first-in-class mitochondria-targeted therapeutic. Research has demonstrated its accumulation in cochlear hair cells via nanoparticle conjugation, with favorable cell survival rates, making it a candidate for hearing preservation.
SS-31 binds to cardiolipin in the inner mitochondrial membrane, stabilizing the electron transport chain, optimizing ATP production, and preventing the mitochondrial permeability transition that triggers cell death.
Selectively binds to cardiolipin, a phospholipid found exclusively in the inner mitochondrial membrane, stabilizing cristae structure.
Prevents cytochrome c peroxidase activity, maintaining electron transport chain efficiency and reducing reactive oxygen species (ROS) generation.
Reduces mitochondrial permeability transition pore (mPTP) opening, the key event that triggers apoptosis in damaged cells.
SS-31 conjugated nanoparticles demonstrated mitochondrial-specific accumulation in cochlear hair cells with improved survival rates.
Directly stabilizes the inner mitochondrial membrane by binding to cardiolipin, preventing the structural collapse that leads to cell death.
Nanoparticle-conjugated SS-31 showed mitochondrial-specific accumulation in cochlear hair cells with favorable survival rates in preclinical models.
By maintaining electron transport chain efficiency, SS-31 optimizes ATP production in energy-demanding cells like cochlear hair cells.
Under clinical investigation for multiple conditions including Barth syndrome, heart failure, and age-related mitochondrial decline.
SS-31 conjugated nanoparticles showed mitochondrial-specific accumulation in cochlear hair cells with favorable survival rates, demonstrating targeted delivery to the inner ear.
SS-31 (Elamipretide) improved mitochondrial function in heart failure patients in Phase II clinical trials, demonstrating human safety and mitochondrial targeting.
SS-31 (Elamipretide) has been evaluated in multiple human clinical trials for heart failure and Barth syndrome, with a generally well-tolerated safety profile. Cochlear application is preclinical.
Research Status
SS-31 has human clinical trial data for cardiac and mitochondrial conditions. Cochlear application is preclinical (Nyberg et al., 2021). The nanoparticle delivery approach for targeted cochlear delivery is investigational.
Regulatory Note
SS-31 (Elamipretide) has received FDA Breakthrough Therapy and Fast Track designations for Barth syndrome. It is not approved for cochlear or hearing indications. Hearing protection applications are investigational.